Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer’s disease patients
Authors:
Open Access
- 2 November 2022
- journal article
- research article
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 14 (1) , 1-19
Abstract
Objective: The purpose of this study was to examine the levels of cerebrospinal fluid (CSF) apolipoprotein E (apoE) species in Alzheimer’s disease (AD) patients. Methods: We analyzed two CSF cohorts of AD and control individuals expressing different APOE genotypes. Moreover, CSF samples from the TgF344-AD rat model were included. Samples were run in native- and SDS-PAGE under reducing or non-reducing conditions (with or without β-mercaptoethanol). Immunoprecipitation combined with mass spectrometry or western blotting analyses served to assess the identity of apoE complexes. Results: In TgF344-AD rats expressing a unique apoE variant resembling human apoE4, a ~35-kDa apoE monomer was identified, increasing at 16.5 months compared with wild-types. In humans, apoE isoforms form disulfide-linked dimers in CSF, except apoE4, which lacks a cysteine residue. Thus, controls showed a decrease in the apoE dimer/monomer quotient in the APOE ε3/ε4 group compared with ε3/ε3 by native electrophoresis. A major contribution of dimers was found in APOE ε3/ε4 AD cases, and, unexpectedly, dimers were also found in ε4/ε4 AD cases. Under reducing conditions, two apoE monomeric glycoforms at 36 kDa and at 34 kDa were found in all human samples. In AD patients, the amount of the 34-kDa species increased, while the 36-kDa/34-kDa quotient was lower compared with controls. Interestingly, under reducing conditions, a ~100-kDa apoE complex, the identity of which was confirmed by mass spectrometry, also appeared in human AD individuals across all APOE genotypes, suggesting the occurrence of aberrantly resistant apoE aggregates. A second independent cohort of CSF samples validated these results. Conclusion: These results indicate that despite the increase in total apoE content the apoE protein is altered in AD CSF, suggesting that function may be compromised.Keywords
Funding Information
- Conselleria d'Educació, Investigació, Cultura i Esport (ACIF/2019/062, ACIF/2019/062)
- Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (PI15/00665, PI15/00665, PI15/00665)
- Fundación Carmen y Severo Ochoa (SEV-2017-0723, SEV-2017-0723, SEV-2017-0723)
- Ministerio de Ciencia, Innovación y Universidades (PID2019-107738RB-I00, PID2019-107738RB-I00, PID2019-107738RB-I00)
- Swedish State Support for Clinical Research (ALFGBG-720931, ALFGBG-720931, ALFGBG-720931)
- Alzheimer's Drug Discovery Foundation (201809-2016862, 201809-2016862, 201809-2016862, RDAPB-201809-2016615)
- Alzheimer's Association (ADSF-21-831376-C, ADSF-21-831381-C and ADSF-21-831377-C, ADSF-21-831376-C, ADSF-21-831381-C and ADSF-21-831377-C, ADSF-21-831376-C, ADSF-21-831381-C and ADSF-21-831377-C, ZEN-21-848495)
- Instituto de Salud Carlos III (PI14/01126, PI17/01019, PI20/01473 and INT16/00171, PI18/00435, PI14/1561, PI17/01896 and PI20/1330, PI18/00893)
- Generalitat de Catalunya (SLT006/17/00125, SLT006/17/00119)
- National Institutes of Health (1R01AG056850-01A1; R21AG056974 and R01AG061566, 1R01AG068398-01)
- Departament de Salut, Generalitat de Catalunya (SLT002/16/00408)
- Vetenskapsrådet (2018-02532, 2017-00915)
- European Research Council (681712)
- Stiftelsen för Gamla Tjänarinnor (FO2019-0228)
- Horizon 2020 Framework Programme (860197)
- European Union Joint Programme - Neurodegenerative Disease Research (JPND2021-00694)
- UK Dementia Research Institute (UKDRI-1003)
- swedish alzheimer foundation (AF-742881)
- Hjärnfonden (FO2017-0243)
- VINNOVA (ALFGBG-715986)
- European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236)
This publication has 67 references indexed in Scilit:
- ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditionsProceedings of the National Academy of Sciences of the United States of America, 2013
- The Apolipoprotein E (APOE) Gene Appears Functionally Monomorphic in Chimpanzees (Pan troglodytes)PLOS ONE, 2012
- Preferential interactions between ApoE-containing lipoproteins and Aβ revealed by a detection method that combines size exclusion chromatography with non-reducing gel-shiftBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2012
- Glycosylation and Sialylation of Macrophage-derived Human Apolipoprotein E Analyzed by SDS-PAGE and Mass SpectrometryMolecular & Cellular Proteomics, 2010
- Apolipoprotein-E forms dimers in human frontal cortex and hippocampusBMC Neuroscience, 2010
- Mechanism underlying apolipoprotein E (ApoE) isoform‐dependent lipid efflux from neural cells in cultureJournal of Neuroscience Research, 2009
- Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up studyThe Lancet Neurology, 2006
- Detection of Apolipoprotein E/Dimeric Soluble Amyloid β Complexes in Alzheimer's Disease Brain SupernatantsBiochemical and Biophysical Research Communications, 1997
- Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3.Journal of Clinical Investigation, 1994
- Apolipoprotein E: Binding to Soluble Alzheimer′s β-AmyloidBiochemical and Biophysical Research Communications, 1993